Research Study

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)
Principal Investigator 
David Maberley

Overview

Body Locations and Systems 
Macular Degeneration
ClinicalTrials.gov# 
NCT02247479
Status 
Closed to Recruitment
Study Start/End 
Nov 16, 2015 to Apr 30, 2018
Locations 
Vancouver General Hospital
Name/Title 
Theresa Wiens, Clinical Trial Coordinator
Phone 
604-875-4111 ext.62544
Purpose of Study 

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.